Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J revises Benadryl topical labels to reduce confusion

This article was originally published in The Tan Sheet

Executive Summary

FDA's warning May 12 to consumers not to swallow Benadryl Extra Strength Itch Stopping Gel is another blow to manufacturer Johnson & Johnson's reputation following multiple high-profile recalls by the firm's subsidiary McNeil Consumer Healthcare (1"The Tan Sheet" May 10, 2010). The agency warned the public not to consume the gel when it discovered 121 adverse event reports linked to cases of mistaken ingestion of the gel - seven of which were serious - between 2001 and 2009. FDA said consumers confused the topical product with Benadryl oral liquid products, which have similar consistency and packaging. The agency did not ask J&J to stop using the umbrella name for the product as it recently asked Novartis to rebrand a Maalox line extension that was not an antacid (2"The Tan Sheet" Feb. 22, 2010). However, J&J has added "For Skin Use Only" to the product labeling and launched consumer studies to identify other causes of confusion

You may also be interested in...



Umbrella Brand Debate Lives On At FDA Naming Workshop

Critics of drug labels' effectiveness say reducing errors in the use of OTC drugs depends largely on a change manufacturers oppose - reining in umbrella branding

Novartis' Maalox Total Relief Rebranding Reflects FDA AER Evolution

FDA's request that Novartis rebrand a Maalox line extension is the latest illustration of the agency taking action based on a relatively small number of serious adverse event reports

Senators, State AGs Differ On Whether Further Federal Regulation Needed For OTC Hearing Aids

Sens. Warren and Grassley say federal regulation is needed to ensure consumers in all states benefit from OTC hearing aids. State AGs, on the other hand, have asked the FDA to “define preemption terms in a way that recognizes the important role state and local entities play in protecting consumers.”

Topics

UsernamePublicRestriction

Register

PS104114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel